
    
      To assess the proportion of patients with donor neutrophil engraftment within 30 days of
      allogeneic transplant; assess the incidence of acute GvHD during the first 100 days after
      transplantation; and assess platelet engraftment, graft failure, chronic GvHD, clinical
      safety, and devise performance.
    
  